Monoclonal antibodies: magic bullets with a hefty price tag

被引：80
作者：
Shaughnessy, Allen F. [1 ]
机构：
[1] Tufts Univ, Sch Med, Boston, MA 02111 USA
来源：
BRITISH MEDICAL JOURNAL | 2012年 / 345卷
关键词：
CONTROLLED PHASE-3 TRIAL; MULTIPLE-SCLEROSIS; ALEMTUZUMAB;
D O I：
10.1136/bmj.e8346
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 9 条
  • [1] [Anonymous], 2012, LANCET, V380, P1792
  • [2] Bourgoin AF, WHAT YOU NEED KNOW F
  • [3] Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
    Cohen, Jeffrey A.
    Coles, Alasdair J.
    Arnold, Douglas L.
    Confavreux, Christian
    Fox, Edward J.
    Hartung, Hans-Peter
    Havrdova, Eva
    Selmaj, Krzysztof W.
    Weiner, Howard L.
    Fisher, Elizabeth
    Brinar, Vesna V.
    Giovannoni, Gavin
    Stojanovic, Miroslav
    Ertik, Bella I.
    Lake, Stephen L.
    Margolin, David H.
    Panzara, Michael A.
    Compston, D. Alastair S.
    [J]. LANCET, 2012, 380 (9856) : 1819 - 1828
  • [4] Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
    Coles, Alasdair J.
    Twyman, Cary L.
    Arnold, Douglas L.
    Cohen, Jeffrey A.
    Confavreux, Christian
    Fox, Edward J.
    Hartung, Hans-Peter
    Havrdova, Eva
    Selmaj, Krzysztof W.
    Weiner, Howard L.
    Miller, Tamara
    Fisher, Elizabeth
    Sandbrink, Rupert
    Lake, Stephen L.
    Margolin, David H.
    Oyuela, Pedro
    Panzara, Michael A.
    Compston, D. Alastair S.
    [J]. LANCET, 2012, 380 (9856) : 1829 - 1839
  • [5] Fanneau de La Horie GC, MAKING BIOL DRUGS MO
  • [6] Herper M, WORLDS MOST EXPENSIV
  • [7] Industrialization of mAb production technology The bioprocessing industry at a crossroads
    Kelley, Brian
    [J]. MABS, 2009, 1 (05) : 443 - 452
  • [8] Staton T, SANOFI PULLS CAMPATH
  • [9] U.S. Food and Drug Administration, BIOS
1